About this Event
Where: Keck Center (Room 100)
This is a workshop from the National Academies of Sciences, Engineering, and Medicine.
Lung cancer is the third most common cancer and the leading cause of cancer-related death in the United States. Relative to other types of cancer, lung cancer often has a poor prognosis. The overall 5 year relative survival rate of patients with lung cancer is less than 18%. More than half of lung cancers have distant metastasis at the time of diagnosis and the 5 year relative survival after distant metastasis is less than 5%.
Annual screening of individuals at high risk for lung cancer with low dose computed tomography (LDCT) can prevent a substantial number of lung cancer related deaths by detecting cancer at an earlier stage. Results from the National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality with LDCT screening. In 2013, on the basis of evidence from the NLST, the U.S. Preventive Services Task Force recommended annual lung cancer screening with LDCT for individuals age 55 to 80, with a history of at least 30 pack years of cigarette smoking, and who are either current smokers or had quit within the past 15 years.
However, there are many challenges associated with broad implementation of LDCT lung cancer screening in clinical practices because the effectiveness of cancer screening programs depends on many different factors, including patient, provider, and health system factors.
This National Academies of Sciences, Engineering, and Medicine workshop will examine these challenges in the implementation of LDCT lung cancer screening programs and consider potential actions to improve implementation. Workshop participants will discuss barriers to implementation of lung cancer screening, strategies for identifying populations eligible for and likely to benefit from screening, decision aids for health care providers and patients, strategies to best provide smoking cessation support, and practical measures for state and national public health surveillance of lung cancer screening.
For more information, contact Cyndi Trang: